Literature DB >> 36120262

Chemotherapy-Induced Dysgeusia and Its Perverse Consequences: A Case Report.

Francisco Pombo1, Carolina Seabra1, Ana João Sá1, Inês Ferreira1.   

Abstract

Dysgeusia is one of the most common side effects of chemotherapy. Still, there is little information given to patients and limited knowledge about its diagnosis and management. We report the case of a patient under a standard regimen of adjuvant chemotherapy treatment (cisplatin and vinorelbine) who developed a life-threatening case of diabetes mellitus decompensation (hyperosmolar hyperglycemic state) resulting from extreme dietary intake due to severe dysgeusia and polydipsia. Dysgeusia is associated with a wide range of chemotherapy drugs. It is a frequent side effect but often overlooked. Self-care strategies and pharmacological agents can be implemented to help ensure better compliance to cancer treatment and improve quality of life.
Copyright © 2022, Pombo et al.

Entities:  

Keywords:  chemotherapy; diabetes mellitus; dysgeusia; polydipsia; quality of life

Year:  2022        PMID: 36120262      PMCID: PMC9467480          DOI: 10.7759/cureus.27908

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  4 in total

Review 1.  A systematic review of dysgeusia induced by cancer therapies.

Authors:  Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-05-22       Impact factor: 3.603

2.  The effects of zinc on radiation-induced dysgeusia: a systematic review and meta-analysis.

Authors:  Woo J Chi; Jeffrey N Myers; Steven J Frank; Ruth A Aponte-Wesson; Adegbenga O Otun; Graciela M Nogueras-González; Yisheng Li; Yimin Geng; Mark S Chambers
Journal:  Support Care Cancer       Date:  2020-11-24       Impact factor: 3.603

3.  Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

Authors:  Makoto Sonobe; Ken-ichi Okubo; Satoshi Teramukai; Kazuhiro Yanagihara; Masaaki Sato; Toshihiko Sato; Fengshi Chen; Kiyoshi Sato; Takuji Fujinaga; Tsuyoshi Shoji; Mitsugu Omasa; Hiroaki Sakai; Ryo Miyahara; Toru Bando; Hiroshi Date
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-25       Impact factor: 3.333

4.  Diabetes mellitus following cisplatin treatment.

Authors:  Daniel N Nan; Marta Fernández-Ayala; Maria E Vega Villegas; Almudena Garcia-Castaño; Fernando Rivera; Marta Lopez-Brea; Jesús González-Macías
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.